<div id="readability-page-1"><p><span>Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report)</span> was upgraded by equities research analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Sunday.</p><p>Other analysts also recently issued research reports about the stock. Piper Sandler  set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday. JPMorgan Chase &amp; Co. increased their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday. Guggenheim raised their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, January 26th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday. Finally, TD Cowen  reiterated a &#34;buy&#34; rating on shares of Adaptive Biotechnologies in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.56.</p><p><b>Get Our Latest Analysis on ADPT</b></p><h2>Adaptive Biotechnologies Stock Down 4.3%</h2><p>Shares of Adaptive Biotechnologies stock opened at $15.77 on Friday. The stock's fifty day moving average is $17.03 and its two-hundred day moving average is $15.23. The company has a market capitalization of $2.41 billion, a PE ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies has a 52 week low of $6.26 and a 52 week high of $20.76. </p><p>Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The business's revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period last year, the company earned ($0.23) earnings per share.  As a group, research analysts anticipate that  Adaptive Biotechnologies will post -0.92 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other news, CEO Chad M. Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the transaction, the chief executive officer owned 2,459,245 shares of the company's stock, valued at $45,348,477.80. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CFO Kyle Piskel sold 2,145 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total transaction of $39,596.70. Following the sale, the chief financial officer directly owned 216,637 shares of the company's stock, valued at $3,999,119.02. The trade was a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,612,461 shares of company stock worth $27,754,413 in the last three months. 6.40% of the stock is owned by company insiders. </p><h2>Institutional Trading of Adaptive Biotechnologies</h2><p>A number of institutional investors have recently made changes to their positions in the business. Sound Income Strategies LLC acquired a new position in  Adaptive Biotechnologies during the 3rd quarter valued at about $30,000.  EverSource Wealth Advisors LLC boosted its holdings in  Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter.  Assetmark Inc. grew its stake in shares of  Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after acquiring an additional 2,708 shares during the last quarter.  Smartleaf Asset Management LLC increased its holdings in shares of  Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company's stock valued at $59,000 after acquiring an additional 3,371 shares in the last quarter.  Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of  Adaptive Biotechnologies by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company's stock valued at $120,000 after purchasing an additional 1,532 shares during the last quarter. Institutional investors and hedge funds own  99.17% of the company's stock. </p><h2>Key Stories Impacting Adaptive Biotechnologies</h2><p>Here are the key news stories impacting Adaptive Biotechnologies this week:</p><ul>   <li><span>Positive Sentiment: </span>Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.</li>    <li><span>Positive Sentiment: </span>Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.</li>    <li><span>Neutral Sentiment: </span>Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a &#34;Moderate Buy&#34; with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.</li>    <li><span>Neutral Sentiment: </span>Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.</li>    <li><span>Negative Sentiment: </span>Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.</li>    <li><span>Negative Sentiment: </span>Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.</li>    <li><span>Neutral Sentiment: </span>Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)</li> </ul><h2>Adaptive Biotechnologies Company Profile</h2> (Get Free Report)<p>Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.  </p><p>The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Adaptive Biotechnologies</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The $650 Million Bet on AI's Future</li><li>The gold chart Wall Street is terrified of…</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>Your Bank Account Is No Longer Safe</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURQVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Adaptive Biotechnologies Right Now?</h2><p>Before you consider Adaptive Biotechnologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.</p><p>While Adaptive Biotechnologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ADPT

<p>Wall Street Zen upgraded Adaptive Biotechnologies (NASDAQ:ADPT) from a "hold" to a "buy" rating. Other analysts, including Piper Sandler and JPMorgan, also raised their price targets to $21.00. The stock is currently rated as a "Moderate Buy" with a consensus target price of $17.56. Despite a recent 4.3% decline, the company reported a revenue increase of 51% year-over-year. Insider trading activity included significant sales by CEO Chad M. Robins and CFO Kyle Piskel. Institutional investors have also increased their stakes in the company recently.</p>

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen